As a typical glucose depletory, glucose oxidase (GOx) has been vigorously studied for tumor starvation therapy.[4] Nevertheless, the complexity of tumor microenvironment, such as hypoxia, high protease level, severely limits the treatment efficiency of GOx‐based starvation therapy.[5] Moreover, persistent and nonspecific glucose exhaustion always leads to unexpected systemic hypoglycemia,[6] which also impeded the clinical translation of GOx‐based therapeutics. Here, HAO1 is linked to neoplasm.